Vaxcyte, Inc.
PCVX
$34.56
$1.665.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.18% | -11.29% | -88.33% | -57.16% | -131.65% |
| Total Depreciation and Amortization | 62.31% | 81.09% | 44.86% | 31.98% | 28.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.94% | 744.16% | 1,560.57% | 81.47% | -20.61% |
| Change in Net Operating Assets | -106.53% | -14.04% | -412.22% | -1,190.27% | 1,253.45% |
| Cash from Operations | 13.52% | -5.49% | -93.48% | -233.66% | -97.50% |
| Capital Expenditure | 47.38% | -418.87% | -1,921.50% | -115.23% | -4,875.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,321.85% | -3,067.48% | 87.66% | 0.79% | 223.96% |
| Cash from Investing | -3,900.92% | -4,215.88% | 75.89% | -0.66% | 61.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 95.50% | 2,879.91% | -79.73% | 1,842.59% | -99.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -228.79% | -258.39% | -164.02% | -354.75% | -- |
| Cash from Financing | 79.41% | 3,020.57% | -79.82% | 1,868.62% | -99.58% |
| Foreign Exchange rate Adjustments | 117.57% | -630.54% | -1,707.69% | 26,256.52% | -1,065.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -348.47% | 3,609.86% | -161.66% | 147.13% | -126.55% |